⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of IKI and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
IKI
↗Toulouse, France
IKI is a French digital health company that has developed URIKI, a connected, portable urine analysis solution designed for at-home health monitoring. The platform measures 10 biomarkers to provide personalized nutritional follow-up, aiming to empower patients with chronic conditions—such as kidney disease, urinary lithiasis, and cardiovascular issues—to manage their health proactively.
The company focuses on digital therapeutics and therapeutic patient education, integrating objective data into the care pathway. By providing tools for both patients and healthcare professionals, IKI seeks to optimize patient care, improve nutritional monitoring, and facilitate collaborative follow-up in home-care settings.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:
Industry:Digital Health
Sub-Industry:Diagnostics / Digital Therapeutics
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (URIKI device)
Modalities:Digital Health, Medical Device
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Théradial (Distribution and optimization of URIKI for chronic kidney disease patients), DOMISANTE (Integration of urinalysis solution for home nursing and hospitalization services)
COMPETITION
Position:Niche Player
Competitors:Gena HealthX, AIDEWA, Vital Track Health, Mefood Omics
LEADERSHIP
Key Executives:
Stéphane Lebrun - Chairman
Jean-Christophe Cau - CEO
LINKS
Website:iki-diag.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with IKI. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.